Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Trial to Evaluate Safety of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer

NCT01961544 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.

NCT NCT01961544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01961544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Trial to Evaluate Safety of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Eisai Korea Inc.
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2013
Completion date
July 31, 2015
Enrollment
101 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms